AGN invited to present its Ifenprodil test resutls @ A.C.C. Earlier this week, the pharmaceutical development company, Algernon Pharmaceuticals Inc. (AGN.c AGNPF), announced that it has been invited to present the results from a study of its Ifenprodil drug at the American Cough Conference next June.
The study showed that Ifenprodil helped reduce patients' 24-hour cough counts significantly.
AGN hopes that Ifenprodil will one day be able to help treat those with chronic cough and idiopathic pulmonary fibrosis.
More here: https://www.paidpromotionalmessages.ca/companies/news/989111/algernon-pharmaceuticals-says-it-has-been-invited-to-present-ipf-and-chronic-cough-study-data-at-american-cough-conference-next-year-989111.html
AGN @ $3.34, MC $5.594M